Literature DB >> 10556549

Enhancement of antibody responses by DNA immunization using expression vectors mediating efficient antigen secretion.

C Svanholm1, L Bandholtz, A Lobell, H Wigzell.   

Abstract

The immune responses elicited in mice, after intradermal (i.d.) immunization with plasmids encoding secreted or intracellular forms of HIV-1 nef, HIV-1 tat or C. pneumoniae omp2 proteins, respectively, were compared. To mediate secretion of these proteins the genes were fused to a heterologous signal sequence from murine heavy chain IgG. The nef- and omp2-specific antibody responses were dramatically increased when mice were inoculated with the plasmid encoding the secreted form of these proteins. In contrast, HIV-1 tat comprising an internal strong nuclear targeting sequence could not be induced to secretion and subsequently no enhanced antibody response was observed. Slight improvement of the HIV-1 nef antibody response was achieved after co-inoculation with a granulocyte-macrophage colony-stimulating factor (GM-CSF) expression vector. Further, nef-specific T-cell responses were induced after nef DNA injections, and were of Th1-like phenotype regardless of whether the nef protein was secreted or not. The system described in this study, using a plasmid vector with a strong heterologous signal sequence that mediate efficient antigen secretion in vivo, may have wide applicability for the induction of high antibody levels to normally non-secreted antigens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556549     DOI: 10.1016/s0022-1759(99)00086-1

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Authors:  Melissa A Cobleigh; Clinton Bradfield; Yuanjie Liu; Anand Mehta; Michael D Robek
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

4.  Specific antibodies to Porphyromonas gingivalis Lys-gingipain by DNA vaccination inhibit bacterial binding to hemoglobin and protect mice from infection.

Authors:  M Kuboniwa; A Amano; S Shizukuishi; I Nakagawa; S Hamada
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  Adjuvant modulation of the immune responses and the outcome of infection with Chlamydia pneumoniae.

Authors:  L Bandholtz; M R Kreuger; C Svanholm; H Wigzell; M E Rottenberg
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

6.  Optimal induction of T-cell responses against hepatitis C virus E2 by antigen engineering in DNA immunization.

Authors:  Jin-Won Youn; Su-Hyung Park; Jae Ho Cho; Young Chul Sung
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.

Authors:  Reinhard Tober; Zoltan Banki; Lisa Egerer; Alexander Muik; Sandra Behmüller; Florian Kreppel; Ute Greczmiel; Annette Oxenius; Dorothee von Laer; Janine Kimpel
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

8.  A Simple and Efficient Genetic Immunization Protocol for the Production of Highly Specific Polyclonal and Monoclonal Antibodies against the Native Form of Mammalian Proteins.

Authors:  Julie Pelletier; Hervé Agonsanou; Fabiana Manica; Elise G Lavoie; Mabrouka Salem; Patrick Luyindula; Romuald Brice Babou Kammoe; Jean Sévigny
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.